Hitachi Medical warns of first-half loss
Hitachi Medical expects to report a net loss of $5.67 million for the half-year ended Sept. 30. The company said that despite strong U.S. sales of MRI and diagnostic ultrasound systems, CT and ultrasound sales in Japan have been weak. Hitachi had
Hitachi Medical expects to report a net loss of $5.67 million for the half-year ended Sept. 30. The company said that despite strong U.S. sales of MRI and diagnostic ultrasound systems, CT and ultrasound sales in Japan have been weak.
Hitachi had projected a profit of $3.02 million for the period. The firm said group sales would likely reach $451 million, some $54.44 million short of the original projection.
A spokesperson for the Hitachi Medical Corporation of America said the ultrasound division in the U.S. had exceeded its sales goals in the past few months. She said the company plans new product introductions at the RSNA show.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
